|Articles|May 1, 2005
- Pharmaceutical Executive-05-01-2005
- Volume 0
- Issue 0
TOC
TOC
Advertisement
Articles in this issue
about 21 years ago
Pharm Exec Ad Starsabout 21 years ago
Elephant or Specialist?about 21 years ago
Global Report: Iron Fistabout 21 years ago
Washington Report: The Pendulum Swingsabout 21 years ago
What Does It Take to be a Global Leader in Trainingabout 21 years ago
Unleash the Tabletsabout 21 years ago
Eisai's New Leadershipabout 21 years ago
Superstar Selectionabout 21 years ago
TOCabout 21 years ago
Professional Persuasion:101Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5